Key Differences Among ALK Inhibitors

Colon cancer recurrence risk falls below 0.5% at 6 years post-surgery, offering a practical benchmark for defining cure, according to new research.

This Managed Care Cast episode explores how high costs and inconsistent insurance coverage for incretin mimetics impact obesity management and patient care.

Amivantamab plus lazertinib enhances survival in NSCLC but requires complex care compared with osimertinib, explained Danny Nguyen, MD, of City of Hope.

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

Raludotatug deruxtecan (R-DXd) earned FDA breakthrough designation for CDH6-expressing platinum-resistant ovarian cancers after bevacizumab (Avastin; Genentech) treatment.

There are clear benefits to starting biologic therapy earlier for severe asthma, as well as initiation patterns by ethnicity, according to data at ERS Congress 2025.